Summit Therapeutics PLC annual earnings per share (EPS) for fiscal TTM was $-1.12, an increase of 22.2% from $-1.44 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-1.12 | $-1.44 | $-0.25 | $-0.78 | $-0.34 | $-0.93 | $-0.55 | $0.15 | $0.13 | $-0.31 | $-0.35 | $-0.34 | $-0.29 | $-0.30 | $-0.27 | $-0.02 | $-0.19 | $-0.08 | $-0.60 | $-0.42 | $-0.16 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-0.28 | $-0.24 | $-0.29 | $-0.31 | $-0.31 | $-0.07 | $-0.07 | $-0.06 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More SMMT metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All SMMT financial statements → Interactive SMMT charts →
About TickerBase · Data methodology & sources · Privacy · Terms